Osteoporosis: Who is the high risk patient and how to treat them | Dyslipidemia and primary and secondary cardiovascular risk reduction (en anglais)

Détails de l'événement

  • 2019/09/24
  • 17:30
  • Restaurant Lezvos West - 4235, Boulevard Décarie, Montréal, QC H4A 3K4
  • Nadine Grunberg, 514 515-3752

Objectifs d'apprentissage

LES PLACES SONT LIMITÉES

À la fin de ces conférences, les participants seront en mesure de :

Osteoporosis: Who Is the high risk patient and how to treat them ?
1. Describe and recognise the prevalence and health burden of osteoporosis including the morbidity and one year mortality of patients sustaining hip fractures;
2. Define clinical risk factors including the fragility fractures associated with high risk osteoporotic patients and integrate this in clinical practice;
3. Describe and learn how to integrate assessment tools including the timed up and go test and FRAX in order to guide decisions on initiation of pharmacological intervention in order to reduce fracture risk;
4. Define and elaborate non pharmacological interventions proven to decrease the risk of fall;
5. Describe the variety of pharmacological interventions available to treat osteoporosis and learn how to choose amongst the variety of agents;
6. In patients treated with bisphosphonates define criteria to identify those patients whom treatment beyond years is recommended and identify patients in whom bisphosphonates can be discontinued and learn when and how to reassess risk.

Dyslipidemia and Primary and Secondary Cardiovascular risk reduction
1. Review and apply the evidence in LDL lowering in both primary and secondary CVD prevention describing the actual and relative risk reduction and NNT as well as the safety date of statins;
2. Elaborate and apply strategies on how to promote lifestyle and dietary changes associated with proven CVD risk reduction;
3. Identify the high risk cardiovascular patients not at LDL-C target in need of a treatment modification following the recommendations of the 2016 Canadian Cardiovascular Society Guidelines for the Management of Dyslipidemia for the Prevention of Cardiovascular Disease in the Adult and learn how overcome treatment challenges;
4. Articulate the definition criteria of familial hypercholesterolemia and formulate an approach treatment;
5. Review the literature and define any indications of ASA use in CVD primary prevention.

Conférenciers

Président de séance : Dr Jonathan Singerman. Conférences données par les Drs Peter Assimakopoulos et Christian Constance.

Horaire

De 17 h 30 à 17 h 45, Accueil
De 17 h 45 à 18 h 15, Repas
De 18 h 15 à 19 h 45, Atelier
De 19 h 45 à 20 h, Pause
De 20 h à 21 h 30, Conférence

Inscription

Pour vous inscrire, merci de contacter Nadine Grunberg, Amgen Canada, au 514 515-3752 ou ngrunber@amgen.com.

Reconnaissance des activités éducatives

L’Association des médecins omnipraticiens de Montréal, sous l’agrément parapluie de la FMOQ, reconnaît 3.00 heures de crédits de catégorie 1 aux participants à cette activité. Numéro FMOQ pour récupérer votre attestation : 71204.

Formation subventionnée

Cette activité bénéficie d’une subvention à visée éducative de Amgen Canada.

Lorem leo Sed elit. lectus commodo ipsum Donec dapibus